Cargando…

Risk assessment of new sequencing information for genetically modified soybean A2704‐12

The GMO Panel has previously assessed genetically modified (GM) soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018,...

Descripción completa

Detalles Bibliográficos
Autores principales: Federici, Silvia, Paraskevopoulos, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7009443/
https://www.ncbi.nlm.nih.gov/pubmed/32625772
http://dx.doi.org/10.2903/j.efsa.2018.5496
_version_ 1783495668309950464
author Federici, Silvia
Paraskevopoulos, Konstantinos
author_facet Federici, Silvia
Paraskevopoulos, Konstantinos
collection PubMed
description The GMO Panel has previously assessed genetically modified (GM) soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean A2704‐12 and to indicate whether the previous conclusions of the GMO Panel on the risk assessment of GM soybean A2704‐12 remain valid. The new sequencing data indicated seven nucleotide differences as compared to the sequence originally provided in application EFSA‐GMO‐NL‐2005‐18; six nucleotides in the 3′ genomic flanking region and one nucleotide in the soybean chloroplast DNA fragment located 5′ to the insert. Another nucleotide located in a polylinker region of the insert reported as ambiguous in the originally submitted sequence was resolved in the new sequence data. Based on the information provided on the locations affected by the reported nucleotide differences, no open reading frames (ORFs) spanning the junction site between the insert and the 3′ genomic flanking DNA are affected by the differences in the 3′ genomic flanking region and were therefore excluded from the assessment. However, one ORF spanning the junction between the 5′‐chloroplast DNA fragment and the insert and six ORFs overlapping with the resolved nucleotide in the polylinker region were affected and therefore assessed. Based on the analysis of the provided data, EFSA considers that it is highly unlikely that the reported sequence differences (including the single nucleotide difference in the 5′‐chloroplast DNA fragment) are due to spontaneous mutations and can therefore most likely be attributed to sequencing errors in the originally reported soybean A2704‐12 event sequence. With the exception of bioinformatic analyses, the studies performed for the risk assessment of soybean A2704‐12 are not affected. The new sequencing data and the bioinformatic analyses performed on the new sequence did not give rise to safety issues. Therefore, EFSA concludes that the original risk assessment of soybean A2704‐12 remains valid.
format Online
Article
Text
id pubmed-7009443
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70094432020-07-02 Risk assessment of new sequencing information for genetically modified soybean A2704‐12 Federici, Silvia Paraskevopoulos, Konstantinos EFSA J EFSA Statement The GMO Panel has previously assessed genetically modified (GM) soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean A2704‐12 and to indicate whether the previous conclusions of the GMO Panel on the risk assessment of GM soybean A2704‐12 remain valid. The new sequencing data indicated seven nucleotide differences as compared to the sequence originally provided in application EFSA‐GMO‐NL‐2005‐18; six nucleotides in the 3′ genomic flanking region and one nucleotide in the soybean chloroplast DNA fragment located 5′ to the insert. Another nucleotide located in a polylinker region of the insert reported as ambiguous in the originally submitted sequence was resolved in the new sequence data. Based on the information provided on the locations affected by the reported nucleotide differences, no open reading frames (ORFs) spanning the junction site between the insert and the 3′ genomic flanking DNA are affected by the differences in the 3′ genomic flanking region and were therefore excluded from the assessment. However, one ORF spanning the junction between the 5′‐chloroplast DNA fragment and the insert and six ORFs overlapping with the resolved nucleotide in the polylinker region were affected and therefore assessed. Based on the analysis of the provided data, EFSA considers that it is highly unlikely that the reported sequence differences (including the single nucleotide difference in the 5′‐chloroplast DNA fragment) are due to spontaneous mutations and can therefore most likely be attributed to sequencing errors in the originally reported soybean A2704‐12 event sequence. With the exception of bioinformatic analyses, the studies performed for the risk assessment of soybean A2704‐12 are not affected. The new sequencing data and the bioinformatic analyses performed on the new sequence did not give rise to safety issues. Therefore, EFSA concludes that the original risk assessment of soybean A2704‐12 remains valid. John Wiley and Sons Inc. 2018-11-26 /pmc/articles/PMC7009443/ /pubmed/32625772 http://dx.doi.org/10.2903/j.efsa.2018.5496 Text en © 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
spellingShingle EFSA Statement
Federici, Silvia
Paraskevopoulos, Konstantinos
Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title_full Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title_fullStr Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title_full_unstemmed Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title_short Risk assessment of new sequencing information for genetically modified soybean A2704‐12
title_sort risk assessment of new sequencing information for genetically modified soybean a2704‐12
topic EFSA Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7009443/
https://www.ncbi.nlm.nih.gov/pubmed/32625772
http://dx.doi.org/10.2903/j.efsa.2018.5496
work_keys_str_mv AT riskassessmentofnewsequencinginformationforgeneticallymodifiedsoybeana270412
AT federicisilvia riskassessmentofnewsequencinginformationforgeneticallymodifiedsoybeana270412
AT paraskevopouloskonstantinos riskassessmentofnewsequencinginformationforgeneticallymodifiedsoybeana270412